Burning Stock Today


USD 3.46  0.05  1.42%   

Market Performance
0 of 100
Odds Of Distress
Over 62
Burning Rock is selling at 3.46 as of the 8th of August 2022; that is -1.42% down since the beginning of the trading day. The stock's lowest day price was 3.34. Burning Rock has more than 62 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Burning Rock Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of July 2022 and ending today, the 8th of August 2022. Click here to learn more.
Fiscal Year End
IPO Date
12th of June 2020
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the Peoples Republic of China. The company was incorporated in 2014 and is headquartered in Guangzhou, China. Burning Rock operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. The company has 104.55 M outstanding shares of which 909.68 K shares are currently shorted by investors with about 0.61 days to cover. More on Burning Rock Biotech

Burning Rock Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Burning Rock's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Burning Rock or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Burning Rock Biotech has very high historical volatility over the last 90 days
Burning Rock Biotech has high likelihood to experience some financial distress in the next 2 years
The company reported the last year's revenue of 536.76 M. Reported Net Loss for the year was (886.67 M) with profit before taxes, overhead, and interest of 364.15 M.
Burning Rock Biotech has about 1.33 B in cash with (509.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Latest headline from finance.yahoo.com: Burning Rock Announces 2022 Annual General Meeting to be Held on September 8, 2022 - Yahoo Finance
President CEO, DirectorVictor Lawrick
Thematic IdeaHealthcare (view all)
Fama & French Classification
Average Analyst Recommendation
Analysts covering Burning Rock report their recommendations after researching Burning Rock's financial statements, talking to executives and customers, or listening in on Burning Rock's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Burning Rock Biotech. The Burning consensus assessment is calculated by taking the average forecast from all of the analysts covering Burning Rock.
Strong Buy3 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Burning Rock Biotech based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Burning Rock Biotech financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares92.9 M104.2 M
Fairly Down
Slightly volatile
Weighted Average Shares Diluted92.9 M104.2 M
Fairly Down
Slightly volatile
Total Assets2.3 B2.3 B
Fairly Up
Slightly volatile
Total Liabilities399.3 M433.3 M
Significantly Down
Slightly volatile
Current Assets1.9 B1.8 B
Notably Up
Slightly volatile
Current Liabilities346.1 M372.2 M
Significantly Down
Slightly volatile
Total Debt84.4 M86.7 M
Fairly Down
Gross Margin0.780.717
Significantly Up
Slightly volatile
Asset Turnover0.220.205
Notably Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Burning Rock's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Burning Rock's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Burning Rock's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Burning Rock's financial leverage. It provides some insight into what part of Burning Rock's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Burning Rock's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Burning Rock deploys its capital and how much of that capital is borrowed.
Burning Rock cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company has 77.48 M in debt with debt to equity (D/E) ratio of 0.05, which may show that the company is not taking advantage of profits from borrowing. Burning Rock Biotech has a current ratio of 4.14, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Burning Rock until it has trouble settling it off, either with new capital or with free cash flow. So, Burning Rock's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Burning Rock Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Burning to invest in growth at high rates of return. When we think about Burning Rock's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(490.46 Million)
Burning Rock Biotech (BNR) is traded on NASDAQ Exchange in USA. It is located in No. 5, Xingdao Ring Road North and employs 1,394 people. Burning Rock is listed under Healthcare category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with total capitalization of 333.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Burning Rock's market, we take the total number of its shares issued and multiply it by Burning Rock's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Burning Rock Biotech runs under Healthcare sector within Diagnostics & Research industry. The entity has 104.55 M outstanding shares of which 909.68 K shares are currently shorted by investors with about 0.61 days to cover. Burning Rock Biotech has about 1.33 B in cash with (509.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Burning Rock Probability Of Bankruptcy
Burning Rock Biotech retains a total of 104.55 Million outstanding shares. 30% of Burning Rock Biotech outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Burning Ownership Details

Burning Stock Price Odds Analysis

What are Burning Rock's target price odds to finish over the current price? In regard to a normal probability distribution, the odds of Burning Rock jumping above the current price in 90 days from now is about 23.63%. The Burning Rock Biotech probability density function shows the probability of Burning Rock stock to fall within a particular range of prices over 90 days. Considering the 90-day investment horizon the stock has a beta coefficient of 1.3935 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Burning Rock will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Burning Rock Biotech is significantly underperforming DOW.
  Odds Below 3.46HorizonTargetOdds Above 3.46
76.30%90 days
Based on a normal probability distribution, the odds of Burning Rock to move above the current price in 90 days from now is about 23.63 (This Burning Rock Biotech probability density function shows the probability of Burning Stock to fall within a particular range of prices over 90 days) .

Burning Rock Historical Income Statement

Burning Rock Biotech Income Statement is one of the three primary financial statements used for reporting Burning's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Burning Rock Biotech revenue and expense. Burning Rock Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Burning Rock Interest Expense is relatively stable at the moment as compared to the past year. Burning Rock reported last year Interest Expense of 1.54 Million. As of 08/08/2022, Preferred Dividends Income Statement Impact is likely to grow to about 94.1 M, while Consolidated Income is likely to drop (817.7 M). View More Fundamentals

Burning Stock Against Markets

Picking the right benchmark for Burning Rock stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Burning Rock stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Burning Rock is critical whether you are bullish or bearish towards Burning Rock Biotech at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Burning Rock without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bond Analysis Now


Bond Analysis

Evaluate and analyze corporate bonds as a potential investment for your portfolios.
All  Next Launch Module

Burning Rock Corporate Management

Elected by the shareholders, the Burning Rock's board of directors comprises two types of representatives: Burning Rock inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Burning. The board's role is to monitor Burning Rock's management team and ensure that shareholders' interests are well served. Burning Rock's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Burning Rock's outside directors are responsible for providing unbiased perspectives on the board's policies.
Edgar Fluri - Member of the Supervisory BoardProfile
Andreas Rittstieg - Member of the Supervisory BoardProfile
Karsten Beckmann - Member of the Management BoardProfile
Henri Nejade - Member of the Management BoardProfile

Invested in Burning Rock Biotech?

You need to understand the risk of investing before taking a position in Burning Rock. The danger of trading Burning Rock Biotech is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Burning Rock is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Burning Rock. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Burning Rock Biotech is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Burning Rock Biotech information on this page should be used as a complementary analysis to other Burning Rock's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Complementary Tools for Burning Stock analysis

When running Burning Rock Biotech price analysis, check to measure Burning Rock's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Burning Rock is operating at the current time. Most of Burning Rock's value examination focuses on studying past and present price action to predict the probability of Burning Rock's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Burning Rock's price. Additionally, you may evaluate how the addition of Burning Rock to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Is Burning Rock's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Burning Rock. If investors know Burning will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Burning Rock listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
369.2 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Burning Rock Biotech is measured differently than its book value, which is the value of Burning that is recorded on the company's balance sheet. Investors also form their own opinion of Burning Rock's value that differs from its market value or its book value, called intrinsic value, which is Burning Rock's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Burning Rock's market value can be influenced by many factors that don't directly affect Burning Rock's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Burning Rock's value and its price as these two are different measures arrived at by different means. Investors typically determine Burning Rock value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Burning Rock's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.